Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
How are you using circulating tumor DNA in your clinical decisions for HPV-associated OPSCC?
Answer from: Radiation Oncologist at Academic Institution
We have a post-operative trial where we are using cfDNA as an integral marker to decide on adjuvant therapy for HPV+ OPC.
Sign in or Register to read more
12429
Related Questions
How should you approach treating curable laryngeal cancer with chemo-RT in a patient who had a myocardial infarction during treatment and requires CABG, given the cardiotoxicity of cisplatin and 5FU/carboplatin?
What is your radiation dose/volume for adjuvant treatment of a clear cell odontogenic carcinoma of the mandible after segmental resection?
How would you best manage C-spine osteoradionecrosis?
Would you recommend adjuvant neck radiation for metastatic chordoma to cervical lymph node, s/p neck dissection, with 1/10 positive nodes and no residual on post op imaging?
Is there a role for prophylactic Trental and vitamin E in a patient at high risk for osteoradionecrosis?
What alternatives do you recommend for oral dexamethasone solution for HN cancer?
What is the recommended treatment approach for stage III/IVA nasopharyngeal cancer that is p16 negative and EBV positive?
What is your experience with Gelclair for oral mucositis during head & neck radiotherapy?
Would you recommend lymph node biopsy in a patient with SCC of the right ventral tongue (~1 cm) post excision with close margins and no noted adenopathy on imaging?
How do you approach a young patient with metastatic poorly differentiated thyroid cancer with rhabdoid/non-anaplastic features?